Nova Eye Medical Ltd
ASX:EYE
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Nova Eye Medical Ltd
ASX:EYE
|
46.9m AUD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.4B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.5B EUR |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.2B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
49.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36B USD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Nova Eye Medical Ltd
Glance View
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia and currently employs 130 full-time employees. The firm is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The firm's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Nova Eye Medical Ltd is 64.5%, which is below its 3-year median of 80.4%.
Over the last 3 years, Nova Eye Medical Ltd’s Gross Margin has decreased from 82.9% to 64.5%. During this period, it reached a low of 64.5% on Jun 30, 2025 and a high of 90.2% on Dec 31, 2023.
